Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

Pfizer said it had now received all regulatory approvals to close the deal on Thursday. The drugmaker in March agreed to buy Seagen and its targeted cancer therapies as it braces for a steep fall in COVID-related sales and generic competition for some top-selling drugs. Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like “guided missiles” designed to destroy cancer while sparing healthy cells.